Nasdaq outperformance vanishes as Dow, S&P score gains after Gilead’s remdesivir update
Link removed as even MarketWatch must have realized how dumb it is and they now just link a general page to the headline.
First of all, I own GILD and am frankly not overly impressed with it. Second, this…
Yes, that’s quite a vanishing act.
An end of summer 2020 price increase is coming. Subscribe to the value-priced NFTRH now to lock in the current rate for the life of your subscription! Current subscribers will never see an increase and have never seen increases since the service began in 2008.
NFTRH Premium (monthly at USD $35.00 or a discounted yearly at USD $365.00) for an in-depth weekly market report, interim market updates and NFTRH+ chart and trade setup ideas. You can also keep up to date with actionable public content at NFTRH.com by using the email form on the right sidebar. Follow via Twitter @NFTRHgt.
